Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy

Figure 1 Overall survival and progression-free survival. A and B: Overall survival (A) and progression-free survival (B) of the following groups: Carbohydrate antigen 19-9 (CA19-9) responder group, CA19-9 non-responder group and CA19-9-negative group. CA19-9 responder group and CA19-9 negative group showed significantly longer overall survival and progression-free survival than CA19-9 non-responder group. CA19-9: Carbohydrate antigen 19-9.

Figure 2 Overall survival and progression-free survival. A and B: Overall survival (A) and progression-free survival (B) of the groups divided by carbohydrate antigen 19-9 response and post-treatment neutrophil-to-lymphocyte ratio. All groups were significantly different from each other in the overall survival and progression-free survival curves and Group 1 showed better overall survival and progression-free survival than others. CA19-9: Carbohydrate antigen 19-9; NLR: Neutrophil-to-lymphocyte ratio.

Figure 3 Overall survival and progression-free survival. A and B: Overall survival (A) and progression-free survival (B) of the carbohydrate antigen 19-9-negative groups according to post-treatment neutrophil-to-lymphocyte ratio (NLR). Post-treatment NLR < 2.62 group showed significantly better overall survival and progression-free survival than post treatment NLR ≥ 2.62. NLR: Neutrophil-to-lymphocyte ratio.